Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,706 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all
Not yet recruiting No phase listed Observational

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

NCT07637942
View directory record Official record
Conditions
HIV -1 Infection
Interventions
Every 4-week long-acting injectable cabotegravir and rilpivirine
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men

NCT03980223
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Syphilis
Interventions
Doxycycline Hyclate Delayed-Release 200 mg
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
641 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 14, 2026, 10:34 AM EDT
Completed No phase listed Observational

Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions

NCT02418494
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, HIV Infection
Interventions
Concept Elicitation, Comprehension Assessment
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Phase 2 Interventional

Improving Coronary Vascular Health in Women

NCT06843902
View directory record Official record
Conditions
HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
Interventions
Health Education, Subspecialty clinic referral
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers

NCT06648629
View directory record Official record
Conditions
HIV-1-infection, Alcohol Drinking
Interventions
Acceptance and Commitment Therapy (ACT), Brief Alcohol Intervention
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed No phase listed Observational

Evaluation and Monitoring of Patients With HIV Infectionn

NCT00557570
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Internet-Based Sexual Health Education for Middle School Native American Youth

NCT01303575
View directory record Official record
Conditions
Sexually Transmitted Diseases, Pregnancy, HIV Infections
Interventions
HIV, STI and Pregnancy Prevention Curriculum, Control Curricula
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
12 Years to 14 Years
Enrollment
574 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
4
States / cities
Anchorage, Alaska • Phoenix, Arizona • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

NCT00472719
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

NCT00002175
View directory record Official record
Conditions
HIV Infections
Interventions
Dinitrochlorobenzene
Drug
Lead sponsor
The Honolulu Medical Group
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 10:34 AM EDT
Completed No phase listed Observational

A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication

NCT01865786
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 14, 2026, 10:34 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization

NCT07219862
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active, INDIVIDUALIZED THERAPY, AIDS (Acquired Immune Deficiency Syndrome), Personalized Medicine, Precision Medicine
Interventions
smART (Smart Antiretroviral Therapy Assistant), Traditional Prescribing resources
Other
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 14, 2026, 10:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CAR-T Cells for HIV Infection

NCT04648046
View directory record Official record
Conditions
HIV Infections
Interventions
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Drug · Biological · Other
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

NCT00833482
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1), HIV Infections
Interventions
Voriconazole, Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 14, 2026, 10:34 AM EDT
Completed No phase listed Observational

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

NCT00096746
View directory record Official record
Conditions
HIV Infection
Interventions
LPV/RTV + 2NRTIs
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • Altamonte Springs, Florida • Fort Lauderdale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 14, 2026, 10:34 AM EDT
Completed No phase listed Observational

Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

NCT00050284
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

NCT00298350
View directory record Official record
Conditions
HIV, HIV-1, Human Immunodeficiency Virus
Interventions
GS-9137 - A Novel HIV-1 Integrase Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 4 Interventional

Buprenorphine and Integrated HIV Care

NCT00317460
View directory record Official record
Conditions
Substance-related Disorders, Drug Addiction, Human Immunodeficiency Virus, AIDS, HIV Infections
Interventions
Physician Management, Counseling
Other · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744

NCT00659191
View directory record Official record
Conditions
HIV Infection
Interventions
GSK1265744
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Nursing Involvement on Implementation of HIV Prevention Services

NCT05095818
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP)
Interventions
PrEP-RN
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

NCT00334659
View directory record Official record
Conditions
HIV Infections
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection

NCT00801879
View directory record Official record
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
Mupirocin calcium ointment, 2%, Placebo ointment
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 14, 2026, 10:34 AM EDT